Leal Therapeutics Announces $45 Million Financing to Progress Novel Therapies for Patients with Major Neurodegenerative and Neuropsychiatric Disorders
Financing supports advancement of lead programs LTX-002 and LTX-001 to first-in-human trials WORCESTER, Mass., Oct. 30, 2024 /PRNewswire/ — Leal Therapeutics, Inc., a biotechnology company developing novel therapeutics for patients with disorders of the central nervous system (CNS),…